Tradestie Institutional Equity Comparison Engine
ZLAB vs CGON โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CGON Overall Edge
CGON Captures Institutional Edge (3โ0 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CG Oncology, Inc. Common stock (CGON) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ZLAB trades at N/M Forward P/E with -63.0% operating margin (-6.8% YoY revenue) versus CGON at N/M Forward P/E and -4293.5% operating margin (-3.7% YoY). In options structure, ZLAB sits in UNCLASSIFIED (58th %ile IV; Dealer Gamma Walls on Pro) against CGON sits in CONSOLIDATION (85th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ZLAB N/M vs CGON N/M Fwd P/E
Growth & Margin Winner
CGON
Op Margin -63.0% vs -4293.5% ยท YoY -6.8% vs -3.7%
Momentum & Technical Winner
CGON
1Y +9.7% vs +124.9% ยท 52W Pos 60% vs 84%
Options & Structure Winner
CGON
UNCLASSIFIED (58th %ile IV) vs CONSOLIDATION (85th %ile IV)
ZLAB
NASDAQ
Zai Lab Limited American Depositary Shares
Pharmaceutical Preparations
$23.83
-3.13% 1D
Market Cap
$3.0B
1M Return
+2.76%
1Y Return
+9.66%
Forward P/E
N/M
Unified AI Score
47.4 / 100
HOLD
Tech 25.0
Fund 39.0
Flow 50.0
Mom 53.5
CGON
NASDAQ
CG Oncology, Inc. Common stock
Biological Products, (No Disgnostic Substances)
$84.94
+14.16% 1D
Market Cap
$6.3B
1M Return
+41.91%
1Y Return
+124.93%
Forward P/E
N/M
Unified AI Score
45.0 / 100
HOLD
Tech 15.0
Fund 44.0
Flow 69.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ZLAB +9.66%
CGON +124.93%
Spread: +115.27 pp (CGON Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ZLAB TTM Op. Margin: -63.0%
CGON TTM Op. Margin: -4293.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZLAB vs CGON. Trailing 12-month operating profitability (ZLAB -63.0% vs CGON -4293.5%) and valuation multiples (ZLAB N/M vs CGON N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ZLAB | CGON | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.0B | $6.3B | Larger Scale | CGON |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -6.8% | -3.7% | Higher Growth | CGON |
| Operating Margin (TTM) Profitability | -63.0% | -4293.5% | Higher Margin | ZLAB |
| Net Profit Margin Profitability | -44.9% | 0.0% | Higher Margin | CGON |
| Return on Equity (ROE) Capital Efficiency | -30.0% | -28.3% | Higher ROE | CGON |
| 52-Week Range Position Momentum | 60% ($16โ$29) | 84% ($37โ$94) | Stronger Trend | CGON |
| Beta / 30D Volatility Risk Regime | 1.19ฮฒ ยท 78% Vol | 0.77ฮฒ ยท 86% Vol | Lower Realized Risk | ZLAB |
| Unified Institutional Score Composite Signal | 47.4 / 100 (HOLD) | 45.0 / 100 (HOLD) | Higher Composite | ZLAB |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ZLAB vs CGON Buy Guide
ZLAB
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
58th %ile
IV Regime
Balanced (25thโ60th %ile)
CGON
CONSOLIDATION
62d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
85th %ile
IV Regime
Extreme (>80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ZLAB nor CGON registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.